


## CorEx

Standalone software  
for comprehensive analysis  
of **CCTA images**

**Powered by CorExtract**



**CorEx is a comprehensive CCTA analysis tool, a deep-learning point-of-care solution that automatically identifies and classifies coronary lesions based on CCTA scans. CorEx also calculates lesion related FFR value at the 0.8 threshold, enabling optimal patient management, in less than one minute<sup>1</sup>.**

**CCTA** is recommended by the ESC and the AHA as the **first line test** for patients with stable chest pain with the **strongest level of evidence** (1A)<sup>2</sup>.

**Ischemia assessment** (FFR  $\leq 0.8$  threshold) is required to make a revascularization decision<sup>3</sup>.

**An AI prediction from a CT scan can be useful for the diagnosis of vessel specific ischemia and may avoid this invasive examination, that, in a majority of cases, leads to unnecessary downstream angioplasty procedures<sup>4</sup>.**

### Module 1

#### Classification CAD-RADS

- Prioritization tool
- Workflow improvement
- Stenosis quantification
- PDF Report
- Second reader effect



**Reveal and Assure**

### Module 2

#### Functional assessment

- FFR prediction at the 0.8 threshold
- Potential reduction of unnecessary ICA
- Potential optimization of patient outcomes & treatment pathways
- FFR calculation by the vessel
- Invasive FFR as ground truth



**Decide**

## CorEx

Comprehensive **CCTA** Analysis

**10**  
validation  
studies

**≈ 1**  
min  
turnaround  
time

**16**  
countries

On-premise  
or Cloud

**2**  
patents  
validated

CE Marked - Not FDA Approved - ISO 13485 Certified

1- Internal reporting testing. With CorEx, we can avoid up to 60% of unnecessary invasive coronarography

2- (NICE 2016 – ESC Guidelines 2019 – US Guidelines [ACC-AHA/SCCT..] 2021)

3- Invasively (FAME trial – Tonino NEJM 2009)/ Non-invasively (US Guidelines [ACC-AHA/SCCT..] 2021).

4- Morgan-Hughes G, Williams MC, Loudon M, Roobottom CA, Veitch A, Van Lingen R, Holloway B, Bellenger N, Schmitt M, Bull R. Downstream testing after CT coronary angiography: time for a rethink? Open Heart. 2021 Feb;8(1):e001597. doi: 10.1136/openhrt-2021-001597. PMID: 33622963; PMCID: PMC7907873

**Module 1**  
Stenosis quantification



**Module 3**  
Plaque characterization  
and quantification

*Under development*


**Module 2**  
Functional assessment

**Automatic Segmentation - CorExtract <sup>NEW</sup>**

- Obtain segmented arteries in less than 10 minutes
- Accelerate physician workflow
- Easily correct centerlines if needed
- Zero-click solution




*CE Marked - Not FDA Approved - ISO 13485 Certified*



**CorEx Explainability - CorExplain**

- Highlights the region of interest
- Provides insight and explainability for clinical user
- Reinforces confidence in reported values
- Reinforcing CCTA education



**CAD RADS <sub>AI</sub>**

Negative Predictive Value	97%*
Accuracy	96%*
Sensitivity	93%*
Specificity	97%*

\*Validation set composed of 159 from 53 consecutive patients - Evaluation of a deep learning model on coronary CT angiography for automatic stenosis detection

**FFR <sub>AI</sub>**

Negative Predictive Value	93%*
Accuracy	84%*
Sensitivity	86%*
Specificity	83%*

\*Validation set composed of 260 patients - Coronary artery disease evaluation during transcatheter aortic valve replacement work-up using photon-counting CT and artificial intelligence